GSK-2190915 sodium salt | B2518

GSK-2190915 sodium is a potent and selective FLAP (5-Lipoxygenase-activating protein) inhibitor (IC₅₀ of 2.6 nM); displays good selectivity over CYP3A4, 2C9, and 2D6. In an acute inflammation setting, GSK-2190915 dose-dependently reduces LTB4, CysLTs, plasma protein extravasation and neutrophil influx induced by peritoneal zymosan injection.

GSK-2190915 sodium is a potent and selective FLAP (5-Lipoxygenase-activating protein) inhibitor (IC₅₀ of 2.6 nM); displays good selectivity over CYP3A4, 2C9, and 2D6. In an acute inflammation setting, GSK-2190915 dose-dependently reduces LTB4, CysLTs, plasma protein extravasation and neutrophil influx induced by peritoneal zymosan injection.

B2518 | GSK-2190915 sodium salt DataSheet

Alternate Name/Synonyms: 3-(3-(tert-butylthio)-1-(4-(6-ethoxypyridin-3-yl)benzyl)-5-((5-methylpyridin-2-yl)methoxy)-1H-indol-2-yl)-2,2-dimethylpropanoate sodium; Fiboflapon sodium; AM-803 sodium

Appearance: Crystalline solid

Formulation:

CAS Number: 1196070-26-4

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: No

Molecular Formula: C₃₈H₄₂N₃NaO₄S

Molecular Weight: 659.81

Cell-Permeable?: True

Purity: ≥98% by HPLC

Solubilities: >30 mg/ml in DMSO

Handling: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

Country of Origin: USA

Tag Line: A potent, selective FLAP inhibitor

MDL Number:

PubChem CID: 44473150

SMILES: CCOC1=NC=C(C=C1)C2=CC=C(C=C2)CN3C4=C(C=C(C=C4)OCC5=NC=C(C=C5)C)C(=C3CC(C)(C)C(=O)[O-])SC(C)(C)C.[Na+]

InChi: InChI=1S/C38H43N3O4S.Na/c1-8-44-34-18-14-28(22-40-34)27-12-10-26(11-13-27)23-41-32-17-16-30(45-24-29-15-9-25(2)21-39-29)19-31(32)35(46-37(3,4)5)33(41)20-38(6,7)36(42)43;/h9-19,21-22H,8,20,23-24H2,1-7H3,(H,42,43);/q;+1/p-1

InChi Key: NOJNFULGOQGBKB-UHFFFAOYSA-M